Alzheimer's disease therapeutic research: the path forward
暂无分享,去创建一个
[1] R. Katzman.,et al. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. , 1976, Archives of neurology.
[2] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[3] M Haupt,et al. [Clinical diagnosis of Alzheimer's disease]. , 1988, Deutsche medizinische Wochenschrift.
[4] A. Smith,et al. Use of structural imaging to study the progression of Alzheimer's disease. , 1996, British medical bulletin.
[5] D. Selkoe,et al. Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.
[6] X. Chen,et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.
[7] A. Schmidt,et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.
[8] M. Raskind,et al. Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis , 1998, Experimental Neurology.
[9] F. Schmitt,et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.
[10] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[11] A. Schmidt,et al. The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.
[12] Rong Wang,et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.
[13] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[14] Steven G Potkin,et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.
[15] B. Winblad,et al. Clinical trials in mild cognitive impairment: lessons for the future , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[16] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[17] D. Bennett,et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.
[18] D. Westaway,et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.
[19] T. Golde,et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice , 2007, BMC Neuroscience.
[20] P. Aisen,et al. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease , 2006, Neurology.
[21] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[22] Nick C Fox,et al. Longitudinal imaging in dementia. , 2007, The British journal of radiology.
[23] J. Ávila,et al. GSK-3 inhibitors for Alzheimer’s disease , 2007, Expert review of neurotherapeutics.
[24] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[25] C. Morissette,et al. Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis , 2007, Neurobiology of Aging.
[26] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[27] S. Hendrix,et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.
[28] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[29] H. Amièva,et al. Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms , 2008, Annals of neurology.
[30] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[31] Mary Sano,et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.
[32] N. Relkin. Current State of Immunotherapy for Alzheimer’s Disease , 2008, CNS Spectrums.
[33] Bruno Vellas,et al. Disease modifying trials in Alzheimer's disease: perspectives for the future. , 2008, Journal of Alzheimer's disease : JAD.
[34] T. Gura. Hope in Alzheimer's fight emerges from unexpected places , 2008, Nature Network Boston.
[35] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[36] G. Zamponi. Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .
[37] John W. Gilbert,et al. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.
[38] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.